Concepedia

Publication | Open Access

Entecavir therapy for lamivudine‐refractory chronic hepatitis B

DOIFull Paper Access

168

Citations

29

References

2008

Year

Morris Sherman, Cihan Yurdaydın, Halis Şimşek, Marcelo José Barbosa Silva, Yun‐Fan Liaw, Vinod K. Rustgi, Hoel Sette, Naoky Tsai, Daniel J. Tenney, James Vaughan,
Hepatology

Abstract

Through 96 weeks of treatment, 1 mg entecavir resulted in continued clinical benefit in lamivudine-refractory HBeAg-positive chronic hepatitis B patients with a safety profile comparable to lamivudine.

References

YearCitations

Page 1